Alto Neuroscience, Inc. (ANRO): Total Liabilities
$33.55M
As of 2025-12-31
$34.82M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $33.55M | +28.6% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $26.08M | +55.0% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $16.82M | n/a | 2025-03-20, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $33.55M | +28.6% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $5.61M | +144.2% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $33.15M | -1.4% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $10.20M | -9.4% |
| PepGen Inc. (PEPG) | 2025-12-31 | $26.46M | -18.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $306.60M | -7.0% |
Compare ANRO, LXRX, FBIO, BNTC side by side · Screen every company in Pharmaceutical Preparations ↗